For Research Use Only. We do not provide direct services or products for patients.
SARS-CoV-2 (B.1.621, Mu Variant) Spike-pseudovirus was prepared by co-transfecting 293T cells with an HIV-1 backbone plasmid and a plasmid containing the SARS-CoV-2 spike encoding gene (Genbank Accession #QHD43416.1; with B.1.621 mutation). The packaged Spike-pseudovirus expresses full-length spike protein on the surface and carries a luciferase reporter gene, which can be used to infect cells that overexpress ACE2, and express luciferase in the cells to characterize infectivity of the virus.
Neutralizing antibody / serum test / As a standard for ELISA and other tests.
Store at -80°C.
The 2019 novel coronavirus, or "SARS-CoV-2", was discovered because of Wuhan virus pneumonia cases in 2019, and was named by the World Health Organization on January 12, 2020. It belongs to the beta genera of the Coronaviridae family, together with SARS coronavirus in 2003 and MERS coronavirus in 2012. The alignment between SARS-CoV-2 and 2003 SARS CoV has about 70% sequence similarity and 40% sequence similarity with MERS CoV. The coronavirus genome encodes a spike protein, an envelope protein, a membrane protein, and a nucleoprotein. Among them, spike protein is the most important surface membrane protein of coronavirus.